ArticleFrontiers in medicine2026
Q fever endocarditis complicating biventricular failure: diagnostic and therapeutic insights from a case report and literature review.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Q fever endocarditis (QFE) is a rare, life-threatening infection caused by Case presentation: We describe a 45-year-old man with dual mechanical valves and ischemic cardiomyopathy who presented in cardiogenic shock with acute decompensated heart failure and cardiogenic shock. Transesophageal echocardiography revealed severe prosthetic mitral valve dehiscence with paravalvular regurgitation. Despite broad empiric antimicrobial therapy, blood cultures remained negative until serologic testing confirmed QFE. His clinical course was complicated by severe biventricular failure, recurrent infections, and refractory fluid overload, requiring continuous renal replacement therapy, prolonged doxycycline-hydroxychloroquine therapy, and intensive multidisciplinary care. Surgical intervention was deferred because of prohibitive operative risk, and the patient ultimately died from multiorgan failure. Literature review: A scoping review of 53 studies, comprising 421 cases on QFE found that patients were predominantly male (77.4%), with a weighted mean age of 53 years. Aortic valve involvement was most frequently reported (57.5% of cases with available valve data), and vegetations were described in 65.1% of cases with reported echocardiographic findings. Blood cultures were negative in 96.2% of cases with available culture data, while Phase I IgG titers ≥1:800 were reported in 83.7% of cases with available serologic data. Doxycycline plus hydroxychloroquine was the most commonly used treatment regimen (52.2%), and cardiac surgery was performed in 58.4% of cases with available surgical data. Reported mortality was 10.6% among cases with available outcome data. Conclusion: This case highlights the diagnostic challenges of QFE in patients with prosthetic valves and underscores the importance of early serologic testing in the setting of culture-negative endocarditis. The accompanying literature synthesis confirms the central role of serology, the frequent need for surgical intervention, and the persistent challenges in achieving definitive cure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.